Prescribing Guides
Ondansetron Prescribing Guide for Indian Clinical Practice
Ondansetron prescribing reference for Indian doctors covering 5-HT3 antagonist pharmacology, PONV and CINV dosing, QT risk and NEET PG points.
MedNext Editorial Team | 2026-08-01 | 8 min read
Ondansetron Prescribing Guide for Indian Clinical Practice
Ondansetron prescribing reference for Indian doctors covering 5-HT3 antagonist pharmacology, PONV and CINV dosing, QT risk and NEET PG points.
Ondansetron is the most widely used 5-HT3 receptor antagonist antiemetic in India, essential in oncology for chemotherapy-induced nausea and vomiting (CINV) and in anaesthesia for post-operative nausea and vomiting (PONV).
Clinical Pharmacology Overview
Ondansetron selectively antagonises serotonin 5-HT3 receptors, which are found peripherally on vagal nerve terminals in the GI tract and centrally in the chemoreceptor trigger zone (CTZ) and nucleus tractus solitarius. Chemotherapy, radiation, and surgical manipulation release serotonin from enterochromaffin cells in the gut mucosa, which activates 5-HT3 receptors to trigger the vomiting reflex.
Pharmacokinetics: Oral bioavailability is approximately 60%. Protein binding is 70-76%. Extensively metabolised by CYP3A4, CYP1A2, and CYP2D6 in the liver. Half-life is 3-6 hours. Metabolites are renally excreted.
Indian Brand Names
- Emeset (Cipla)
- Ondem (Alkem Laboratories)
- Vomikind (Mankind Pharma)
- Zofer (Sun Pharma)
- Ondaz (Zydus Cadila)
Approved Indications in Indian Clinical Practice
- Chemotherapy-induced nausea and vomiting (CINV) -- highly and moderately emetogenic regimens
- Radiation-induced nausea and vomiting
- Post-operative nausea and vomiting (PONV) -- prophylaxis and treatment
- Hyperemesis gravidarum (off-label but widely used in India)
- Post-anaesthesia nausea in day-care surgery
Dosing in Adults
CINV (highly emetogenic): 8 mg IV before chemotherapy, then 8 mg orally every 12 hours for 1-2 days. Often combined with dexamethasone and aprepitant.
CINV (moderately emetogenic): 8 mg orally 30 minutes before chemotherapy, then 8 mg 8 hours later, then 8 mg every 12 hours for 1-2 days.
PONV prophylaxis: 4 mg IV at induction of anaesthesia.
PONV treatment: 4 mg IV.
Hyperemesis gravidarum: 4-8 mg orally or IV every 8-12 hours.
Maximum single IV dose: 16 mg (due to QT prolongation risk).
Important Drug Interactions
- QT-prolonging drugs (haloperidol, droperidol, erythromycin, fluoroquinolones): additive QT prolongation
- Apomorphine: concurrent use contraindicated (risk of profound hypotension and loss of consciousness)
- Tramadol: ondansetron may reduce analgesic efficacy of tramadol (5-HT3 pathway contributes to tramadol analgesia)
- Serotonergic drugs (SSRIs, SNRIs): theoretical serotonin syndrome risk (rare)
- CYP3A4 inducers (rifampicin, phenytoin): may reduce ondansetron levels
Side Effects and Monitoring
Common: headache (most frequent), constipation, dizziness, fatigue.
Serious: QT prolongation and risk of torsades de pointes (dose-dependent), serotonin syndrome (rare, with concurrent serotonergic drugs), hepatotoxicity (rare).
Rare: extrapyramidal reactions (much less common than with metoclopramide).
Monitoring: ECG in patients with cardiac risk factors or electrolyte abnormalities. Electrolytes (potassium, magnesium) before administering in high-risk patients.
Special Populations
Pregnancy: Category B. Widely used in India for hyperemesis gravidarum. Small studies suggest possible cleft palate risk in first trimester -- use after first-line agents have failed.
Renal impairment: No dose adjustment needed.
Hepatic impairment: Maximum daily dose 8 mg in severe hepatic impairment (reduced clearance).
Elderly: No specific dose adjustment. Monitor for QT prolongation.
Children: 0.1-0.15 mg/kg IV (max 4 mg) for PONV.
NEET PG High-Yield Points
- Selective 5-HT3 receptor antagonist -- acts peripherally and centrally
- Drug of choice for CINV (especially highly emetogenic chemotherapy)
- Constipation and headache are the two most common side effects
- QT prolongation is dose-dependent -- max single IV dose 16 mg
- Ondansetron reduces tramadol efficacy (shared 5-HT3 pathway)
- Antiemetic classification: 5-HT3 antagonists, D2 antagonists, NK1 antagonists, antihistamines, anticholinergics, cannabinoids
- Does NOT cause extrapyramidal symptoms (unlike metoclopramide)
- Acts on CTZ and vagal afferents -- dual site of action
Indian Regulatory Status
Ondansetron is a Schedule H drug under the Drugs and Cosmetics Act. It is included in the NLEM of India. Available as oral tablets, orally disintegrating tablets (ODT), oral solution, and injection. The injectable form is widely used in hospital settings. Price is regulated under DPCO for listed formulations.
Frequently Asked Questions
How does ondansetron work as an antiemetic?
Ondansetron selectively blocks 5-HT3 (serotonin type 3) receptors both peripherally on vagal nerve terminals in the GI tract and centrally in the chemoreceptor trigger zone (CTZ) and nucleus tractus solitarius. Chemotherapy and radiation release serotonin from enterochromaffin cells, which triggers emesis via these pathways.
What is the QT prolongation risk with ondansetron?
Ondansetron can prolong the QT interval in a dose-dependent manner. The single IV dose should not exceed 16 mg (US FDA recommendation). Use with caution in patients with congenital long QT syndrome, electrolyte abnormalities, or those on other QT-prolonging drugs. Obtain an ECG in high-risk patients.
Is ondansetron safe in pregnancy?
Ondansetron (Category B) is widely used for hyperemesis gravidarum in India. Some studies have suggested a small increased risk of cleft palate with first-trimester use, but the absolute risk is very low. It is generally reserved for severe nausea not responding to first-line agents like doxylamine-pyridoxine.
Can ondansetron cause constipation?
Yes. Constipation is one of the most common side effects because 5-HT3 blockade slows colonic transit. This can be particularly problematic in post-operative patients and those on opioids. Headache is the other very common side effect.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides